Back grey_arrow_rt.gif
 
Hepatitis D (Delta)
 
null.gif
 
 
  1. HEPATITIS D INFECTION: who should be screened AASLD 2018 HBV Guidelines - (05/27/22)
     
  2. Hepatitis D Changing Context Global Prevalence - (02/10/22)
     
  3. EASL: Efficacy and Safety of Bulevirtide Monotherapy Given at 2 mg or 10 mg Dose Level Once Daily for Treatment of Chronic Hepatitis Delta: Week 48 Primary Endpoint Results From a Phase 3 Randomized, Multicenter, Parallel Design Study - (06/24/22)
     
  4. AASLD: Bulevirtide Improves Health-Related Quality of Life Measured by EQ-5D VAS in Patients With Chronic Hepatitis Delta: An Exploratory Analysis of a Phase 3 Trial at 48 Weeks - (11/15/22)
     
  5. AASLD: Compassionate use of subcutaneously administered REP 2139-Mg in cirrhotic HBV / HDV co-infection - (11/14/22)
     
  6. AASLD: Evaluating Hepatitis Delta Virus Disease Prevalence and Patient Characteristics Among Hospitalized Adults in Italy - (11/14/22)
     
  7. AASLD: Impact of Reflex Testing on the Delta Hepatitis Disease Burden in France - (11/14/22)
     
  8. AASLD: Bulevirtide Improves Health-Related Quality of Life Measured by EQ-5D VAS in Patients With Chronic Hepatitis Delta: An Exploratory Analysis of a Phase 3 Trial at 48 Weeks - (11/14/22)
     
  9. AASLD: OVERCOMING BARRIERS TO CARE FOR DELTA INFECTED PATIENTS - (11/14/22)
     
  10. AASLD: Treatment with Bulevirtide, with or without PEG-interferon, in HDV infected patients in a real-life setting. Two-year results from the French multicenter early access program - (11/14/22)
     
  11. AASLD: Treatment with Bulevirtide, with or without PEG-interferon, in HDV infected patients in a real-life setting. Two-year results from the French multicenter early access program - (11/11/22)
     
  12. AASLD: Extension of Bulevirtide Monotherapy to 72 Weeks in HDV Patients with Compensated Cirrhosis: Efficacy and Safety From the Italian Multicenter Study (HEP4Di) Interim Analysis - (11/11/22)
     
  13. AASLD: HDV Patient Perspective: The Impact of Disease and Current Unmet Needs - (11/10/22)
     
  14. AASLD: Bulevirtide, with or without peg- interferon, in HDV infected patients in a real-life setting. two-year results from the French multicenter early access program - Mark Mascolini (11/09/22)
     
  15. AASLD: Benefit of regular screening for hepatitis delta and subsequent cirrhosis among chronic hepatitis B carriers - (11/09/22)
     
  16. AASLD: Estimating Hepatitis Delta Prevalence Among High-Risk Populations (HIV, MSM, PWID) in the United States: A Systematic Review - (11/09/22)
     
  17. AASLD: Hep D Rate 9% in Tested California Safety-Net Group (immigrants, ethnic minorities) With HBV - Mark Mascolini (11/09/22)
     
  18. AASLD: Hep D Rate 9% in Tested California Safety-Net Group (immigrants, ethnic minorities) With HBV - Mark Mascolini (11/09/22)
     
  19. AASLD: Bulevirtide Monotherapy Is Safe and Well Tolerated in Patients With Chronic Hepatitis D (CHD): An Integrated Safety Analysis of 48-Week Data - (11/09/22)
     
  20. AASLD: The Delta Delta: Gaps in Screening Patterns, Patient Assessment and Clinical Outcomes in Hepatitis D Virus Infection - (11/09/22)
     
  21. AASLD: HDV Prevalence Ranges Widely in US High-Risk Groups: Newer Data Needed - Mark Mascolini - (11/09/22)
     
  22. AASLD: CURE OF HEPATITIS DELTA INFECTION FOLLOWING 3 YEARS OF BULEVIRTIDE MONOTHERAPY IN A PATIENT WITH COMPENSATED ADVANCED CIRRHOSIS - (11/08/22)
     
  23. AASLD: Efficacy of Bulevirtide as Monotherapy for Chronic Hepatitis D (CHD): Week-48 Results From an Integrated Analysis - (11/04/22)
     
  24. AASLD: Evaluating Hepatitis Delta Virus Disease Prevalence and Patient Characteristics Among Hospitalized Adults in Italy - (11/04/22)
     
  25. AASLD: Population adjusted prevalence of hepatitis Delta virus in 16 countries and territories - (11/04/22)
     
  26. AASLD: HDV Load Drops, Liver Markers Improve With Bulevirtide for 48 Weeks - Mark Mascolini (11/04/22)
     
  27. AASLD: BARRIERS TO HEPATITIS DELTA SCREENING: THE POINT OF VIEW OF FRENCH BIOLOGISTS - (11/04/22)
     
  28. Time for universal screening for hepatitis D - A study describing screening patterns, characteristics, and outcomes of hepatitis D virus infection - (11/03/22)
     
  29. Gilead Receives Complete Response Letter from U.S. FDA for Bulevirtide for the Treatment of Adults with Hepatitis Delta Virus - (10/29/22)
     
  30. ID Week: Hepatitis D Virus and Hepatitis B Virus Epidemiology in Utah - (10/24/22)
     
  31. HDV/HBV+ Immigrants in USA - (10/03/22)
     
  32. HDV Prevalence in USA - (10/03/22)
     
  33. High HDV rates Among PWID - (09/29/22)
     
  34. Vir Biotechnology Announces First Patient Dosed in the Phase 2 SOLSTICE Trial Evaluating VIR-2218 and VIR-3434 for the Treatment of Chronic Hepatitis D Virus Infection - (09/29/22)
     
  35. HBV Meeting Paris: Strong decline of intrahepatic HDV markers and signs of liver inflammation after 48 weeks of treatment with Bulevirtide in chronic hepatitis D patients: Combined intrahepatic results from the clinical trials MYR203 and MYR301 - (09/26/22)
     
  36. EASL: Characterizing of hepatitis B virus serum RNA kinetics during TDF plus pegylated interferon alfa-2a with and without nucleic acid polymers - (07/18/22)
     
  37. EASL: Compassionate use of subcutaneous REP 2139-Mg in cirrhotic HBV / HDV coinfection - (07/21/22)
     
  38. EASL: Bulevirtide treatment of hepatitis D in Germany: multicentre real-world experience - (07/21/22)
     
  39. EASL: Improvement of liver-stiffness in HBV/HDV-coinfected patients treated with Bulevirtide - (07/21/22)
     
  40. EASL: Gilead to Present Latest Data From Across Liver Disease Development Programs at the International Liver Congress™ 2022 - (07/11/22)
     
  41. EASL: Hepatitis delta virus reflex testing in patients with hepatitis B dramatically improves the HDV screening cascade: 10 years of real-world experience from Avicenne University Hospital, France - (07/08/22)
     
  42. EASL: Provider Factors Shaping Hepatitis Delta Screening - (07/08/22)
     
  43. EASL: Validation of an internal hepatitis D virus RNA Quantitative assay: Developing an assay suitable for global clinical application and clinical trials assessment - (07/08/22)
     
  44. EASL: Strong correlation between HBsAg, ALT and HDV-RNA levels in patients with chronic hepatitis D. Results of Phase 3 D-LIVR study. - (07/06/22)
     
  45. EASL: Clinical features predictive of cirrhosis in a large cohort of patients with chronic hepatitis delta infection - Insights from the D-LIVR trial - (07/06/22)
     
  46. EASL: Peg-Lambda HDV-RNA Kinetics Math Modeling LIMT-1 Study - (07/06/22)
     
  47. EASL: Rising Clinical and Economic Burden Among Hepatitis D Patients Who Attended Spanish Hospitals - (07/02/22)
     
  48. EASL: Impact of Patient-Related Factors on the Pharmacokinetics of Bulevirtide - (07/02/22)
     
  49. EASL: Polymorphic Analysis of Bulevirtide Sequence in preS1 of Large HBsAg Across HBV Genotypes A-H - (07/02/22)
     
  50. EASL: Integrated Safety Analysis of 24-Week Data From Three Phase 2 and One Phase 3 Clinical Trial of Bulevirtide Monotherapy Given at 2- or 10-mg Dose Level for Treatment of Chronic Hepatitis Delta - (07/02/22)
     
  51. EASL: Peginterferon Lambda (IFN-λ) combined with Lonafarnib diminished triphasic HDV kinetic pattern seen under IFN-λ monotherapy: The LIFT-1 Study - (07/02/22)
     
  52. EASL: Mathematical modeling of HDV RNA kinetics suggests high peginterferon lambda efficacy in blocking viral production: Insights from the LIMT-1 study - (07/02/22)
     
  53. EASL: Estimating the Prevalence of Hepatitis Delta Infection among Foreign-Born Adults with Chronic Hepatitis B in the United States - (07/02/22)
     
  54. EASL: Hepatitis Delta Management in the United States: An Analysis Of All-Payer Claims Database - (07/02/22)
     
  55. EASL: Healthcare Resource Utilization and Costs of Hepatitis Delta in the United States: An Analysis of All-Payer Claims Database - (07/02/22)
     
  56. EASL: One Third With HDV Respond to Bulevirtide Monotherapy Through 24 Weeks (2 & 10 mg) - Integrated Analysis from 2 Phase 2 & 1 Phase 3 Trials - Mark Mascolini - (07/01/22)
     
  57. EASL: Evidence of Past Hepatitis C and D Co-Infection in Hepatitis B Seronegative Individuals - (06/27/22)
     
  58. EASL: EASL 2022 HBV, HDV Wrap-Up - (06/27/22)
     
  59. EASL: Peginterferon Lambda (IFN-λ) combined with Lonafarnib diminished triphasic HDV kinetic pattern seen under IFN-λ monotherapy: The LIFT-1 Study - (06/27/22)
     
  60. EASL: Real life study of bulevirtide in chronic hepatitis Delta: preliminary results of the ANRS I MIE HD EP01 HDV prospective cohort - (06/26/22)
     
  61. EASL: Evaluating Hepatitis Delta Virus Disease Prevalence and Patient Characteristics Among Adults in the United States: An Analysis of All-Payer Claims Database - (06/25/22)
     
  62. EASL: Association between Hepatitis Delta Virus with Liver Morbidity and Mortality: A Systematic Literature Review and Meta-Analysis - (06/25/22)
     
  63. EASL: Response-guided long-term treatment of chronic hepatitis D patients with bulevirtide -Results of a "real world study" - (06/25/22)
     
  64. EASL: No Detectable Resistance to Bulevirtide in Participants With Chronic Hepatitis D Through 24 Weeks of Treatment - (06/25/22)
     
  65. EASL: Efficacy and Safety of Bulevirtide Monotherapy Given at 2 mg or 10 mg Dose Level Once Daily for Treatment of Chronic Hepatitis Delta: Week 48 Primary Endpoint Results From a Phase 3 Randomized, Multicenter, Parallel Design Study - (06/24/22)
     
  66. EASL: Integrated efficacy analysis of 24-week data from two phase 2 and one phase 3 clinical trials of bulevirtide monotherapy given at 2 mg or 10 mg dose level for treatment of chronic hepatitis delta - Mark Mascolini (06/24/22)
     
  67. Global Hepatitis D 37% Prevalence in IVDUs - (06/14/22)
     
  68. About the Phase 3 D-LIVR Study: oral Lonagarnib/rtv +/- Peg-Lambda 48 weeks - (06/13/22)
     
  69. Persistent Control of Hepatitis B Virus and Hepatitis Delta Virus Infection Following REP 2139-Ca and Pegylated Interferon Therapy in Chronic Hepatitis B Virus/Hepatitis Delta Virus Coinfection - (06/08/22)
     
  70. Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial - (06/07/22)
     
  71. Efficacy of prolonged tenofovir therapy on hepatitis delta in HIV-infected patients - (06/07/22)
     
  72. PREVALENCE OF HEPATITIS DELTA VIRUS (HDV) INFECTION IN THE UNITED STATES: RESULTS FROM AN ICD-10 REVIEW - 25% of HDV in USA is In NYC (Bklyn, Bronx) & NYC Suburb - (06/06/22)
     
  73. A Phase 2 Study of Lonafarnib, Ritonavir & Peginterferon Lambda for 24 Weeks: Interim End-of-Treatment Results from the LIFT HDV Study - (05/31/22)
     
  74. Treatment for hepatitis delta virus with the prenylation inhibitor lonafarnib: It's getting closer Editorial - (05/31/22)
     
  75. Optimizing lonafarnib treatment for the management of chronic delta hepatitis: The LOWR HDV-1 study - (05/31/22)
     
  76. Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease - (05/31/22)
     
  77. Lonafarnib-A new member of the Delta Force? Editorial - (05/27/22)
     
  78. A phase 2 dose-finding study of lonafarnib and ritonavir with or without interferon alpha for chronic delta hepatitis - (05/27/22)
     
  79. Eiger BioPharmaceuticals Announces Complete Enrollment of D-LIVR, the Largest Phase 3 Study in Hepatitis Delta Virus (HDV), Investigating Lonafarnib, the Only Oral Agent in Development for HDV - (05/27/22)
     
  80. HEPATITIS D INFECTION: who should be screened AASLD 2018 HBV Guidelines - (05/27/22)
     
  81. Gilead Submits Biologics License Application to U.S. Food and Drug Administration for Bulevirtide, an Investigational Treatment for People Living With Chronic Hepatitis Delta - (05/26/22)
     
  82. Delta hepatitis within the Veterans Affairs medical system in the United States: Prevalence, risk factors, and outcomes - (05/26/22)
     
  83. Hepatitis D Changing Context Global Prevalence - (02/10/22)
     
  84. Gilead Submits Biologics License Application to U.S. Food and Drug Administration for Bulevirtide, an Investigational Treatment for People Living With Chronic Hepatitis Delta - (12/10/21)
     
  85. AASLD: Hepatitis D Delta Overview; New AASLD 2021 Treatment Studies (12/06/21)
     
  86. AASLD: Hepatitis D (Delta) at AASLD 2021 (12/06/21)
     
  87. AASLD: EFFICACY OF LONG-TERM TREATMENT OF CHRONIC HEPATITIS D PATIENTS WITH BULEVIRTIDE - RESULTS OF A "REAL WORLD" STUDY (11/23/21)
     
  88. AASLD: HDV Hospital Admissions Rare-But Sometimes Severe-in United States - Mark Mascolini (11/20/21)
     
  89. AASLD: MOLECULAR AND CLINICAL EPIDEMIOLOGY OF HEPATITIS D VIRUS INFECTION IN CANADA - (11/19/21)
     
  90. AASLD: Low adherence to guidelines recommendations for hepatitis D testing in HBsAg-positive patients leads to high undiagnosis rates - (11/19/21)
     
  91. AASLD: Hepatitis D-Associated Hospitalizations in the United States: 2010-2018 - (11/19/21)
     
  92. AASLD: Over 90% of Clinicians Ignore EACS Hep D Screening Advice - Mark Mascolini (11/19/21)
     
  93. AASLD: Safety and Efficacy of 2 mg Bulevirtide in Patients with Chronic HBV/HDV Co-Infection: First Real-World Results - (11/17/21)
     
  94. AASLD: Prevalence and Characteristics of Hepatitis Delta in the United States: an Analysis of All-Payer Claims Databases - (11/17/21)
     
  95. AASLD: ETHNIC VARIATIONS IN CLINICAL PRESENTATION AND TREATMENT ELIGIBILITY FOR HEPATITIS DELTA VIRUS INFECTION AT A US REFERRAL CENTER - (11/17/21)
     
  96. AASLD: Strong intrahepatic decline of hepatitis D virus RNA and antigen after 48 weeks of treatment with Bulevirtide in chronic HBV/HDV co-infected patients: Interim results from a multicenter, open-label, randomized phase 3 clinical trial (MYR301) - (11/16/21)
     
  97. AASLD: HDV seropositivity was common amongst HBsAg+ women enrolled in WIHS. 26 (22%) of the 117 HBsAg+ women were HDV seropositive - (11/12/21)
     
  98. Safety and effectiveness of up to 3 years- bulevirtide monotherapy in patients with HDV-related cirrhosis - (10/25/21)
     
  99. EASL: Safety and Efficacy of Bulevirtide Monotherapy and in Combination with Peginterferon Alfa-2a in Patients with Chronic Hepatitis Delta: 24 Weeks Interim Data of MYR204 Phase 2b Study - Mark Mascolini (06/27/21)
     
  100. EASL: Bulevirtide With or Without PEG-IFN Shows 24-Week Activity Against Hep D - Mark Mascolini (06/27/21)
     
  101. EASL: Bulevirtide Monotherapy at Low and High Doses in Patients With Chronic Hepatitis Delta: 24-Week Interim Data of the Phase 3 MYR301 Study - (06/24/21)